Cbd education

Posted on by admin

CBD 101: An Introductory Course

CBD (in the form of oils, creams, lotions, edibles and more) has entered mainstream America! Their presence has been noted in the fields of food and beverages, cosmetics, and pharmaceuticals. With projections for this industry to surpass $20 billion dollars by the year 2024, healthcare providers need to be aware of the ever-growing consumer usage, as well as the medical and legal implications for its users.

CBD is defined as cannabidiol. It is an active chemical in the Cannabis Sativa plant (also known as marijuana or hemp). While CBD is one of over 80 chemicals known as cannabinoids, by itself it does not cause a “high.” According to the World Health Organization, CBD exhibits no effects indicative of any abuse or dependence potential. Furthermore, to date, there is no evidence of public health-related problems associated with the use of pure CBD. The issue at hand is actually the origin of the CBD ingredients. While delta-9-tetrahydrocannabinol (THC) is the major active ingredient in marijuana, cannabidiol is also obtained from hemp, which contains only very small amounts of THC. The purpose of the continuing education program is to inform and educate healthcare providers on the various forms of CBD and their usage in mainstream medicine.

Objectives

Upon completion of this course, participants will be able to:

  1. Discuss the origins of CBD usage.
  2. Verbalize differences between marijuana-based and hemp-based CBD products.
  3. Identify recognized usages for CBD (disease-specific).
  4. Discuss route of administration for CBD usage.
  5. Discuss components of the farming hemp bill.
  6. Verbalize federal laws related to CBD usage (healthcare workers and urine drugs screens).
  7. Discuss medical marijuana act/medical compassion act.
  8. Identify state rules regarding CBD.
  9. Acknowledge the need for additional research to identify CBD based products that offer optimal benefit with minimal risk.

Curriculum

Chapter 2: History of CBD

Chapter 3: The Endocannabinoid System

  • Ingested
  • Sublingual
  • Topical
  • Inhaled
  • Insufficient Evidence
  • The Entourage Effect
  • National Institutes Of Health (NIH) Views On CBD
  • Centers For Disease Control and Prevention (CDC) and CBD
  • World Health Organization (WHO) and CBD
  • Legal Issues: Urine Drug Screens

Chapter 10: CBD And The American Cannabis Nurse Association (ACNA)

  • California Bill 241
  • Implicit Bias in Healthcare
  • What is Implicit Bias?
  • Implications of Implicit Bias in Healthcare
  • How to Reduce Implicit Bias